Rev M10 gene therapy

Drug Profile

Rev M10 gene therapy

Latest Information Update: 20 Jul 2000

Price : $50

At a glance

  • Originator University of Michigan
  • Class Antivirals; Gene therapies
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 20 Jul 2000 No-Development-Reported for HIV infections treatment in USA (IV)
  • 22 Jun 2000 Warner-Lambert has merged with Pfizer
  • 21 Jan 1997 Phase-II clinical trials for HIV infections treatment in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top